Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 2,505 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Thomas Diraimondo sold 2,505 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $34,393.65. Following the completion of the transaction, the insider owned 124,425 shares in the company, valued at $1,708,355.25. The trade was a 1.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX traded down $0.15 during trading on Friday, hitting $13.65. 1,533,974 shares of the company’s stock were exchanged, compared to its average volume of 2,182,684. The business’s 50-day simple moving average is $22.51 and its 200 day simple moving average is $23.74. The company has a market cap of $821.05 million, a price-to-earnings ratio of -8.13 and a beta of 2.88. Janux Therapeutics, Inc. has a 52-week low of $13.52 and a 52-week high of $61.59.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on JANX shares. Wedbush reiterated an “outperform” rating and issued a $45.00 price target (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Wednesday, October 8th. Truist Financial initiated coverage on Janux Therapeutics in a research report on Wednesday, September 10th. They issued a “buy” rating and a $100.00 target price on the stock. UBS Group reissued a “buy” rating and set a $57.00 price target on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Finally, HC Wainwright reduced their price objective on Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $61.08.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its position in Janux Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after buying an additional 404 shares during the period. ProShare Advisors LLC increased its position in shares of Janux Therapeutics by 8.1% during the second quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock worth $238,000 after acquiring an additional 771 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after acquiring an additional 820 shares in the last quarter. Virtus Investment Advisers LLC boosted its holdings in shares of Janux Therapeutics by 37.9% in the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock valued at $85,000 after purchasing an additional 1,011 shares during the period. Finally, MetLife Investment Management LLC grew its stake in Janux Therapeutics by 7.9% in the first quarter. MetLife Investment Management LLC now owns 18,663 shares of the company’s stock worth $504,000 after purchasing an additional 1,365 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.